ERBB2 and non-small cell lung carcinoma: Thereafter, the phase II DESTINY-Lung01 trial evaluated the efficacy and safety of T-DXd at the dose of 6.4 mg/kg in HER2-mutant or overexpressed, recurrent, or refractory NSCLC.